Alembic Pharma Gets Interim USFDA Approval for Depression Drug

Alembic Pharmaceuticals Ltd announced on Friday that it had received interim approval from the US health regulator for its generic vortioxetine tablets indicated for the treatment of major depressive disorder.

The interim approval granted by the United States Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for vortioxetine 5 mg, 10 mg, 15 mg and 20 mg tablets, indicated the company in a press release.

These are therapeutically equivalent to the Reference Drug Product (RLD) 5 mg, 10 mg, 15 mg and 20 mg Trintellix tablets from Takeda Pharmaceuticals, USA, Inc, he added.

Citing data from IQVIA, the company said that these vortioxetine tablets have an estimated market size of $ 1,249 million for a twelve-month period ending in September 2021.

Alembic, however, said he is currently in litigation with H Lundbeck in the Federal Circuit Court of Appeals and that the product launch will depend on the outcome of the litigation.

“Our ANDA may not be listed for some uses due to unexpired RLD exclusives for such uses,” the company said.

(Only the title and image of this report may have been reworked by Business Standard staff; the rest of the content is automatically generated from a syndicated feed.)

Dear reader,

Business Standard has always strived to provide up-to-date information and commentary on developments that matter to you and have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times resulting from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative views and cutting-edge commentary on relevant current issues.
However, we have a demand.

As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital editor

About Margie Peters

Check Also

Profit Strategy: Psychiatric Facilities Prioritize Out-of-State Children

South Carolina children who need immediate, 24-hour psychiatric care risk being stranded for days or …